Novo Nordisk has initiated its first Phase I trial with a long-acting oral GLP-1 analogue (NN9924), triggering a $2 million milestone payment to development partner Emisphere Technologies. GLP-1 (Glucagon-Like Peptide-1) is a natural hormone involved in controlling blood sugar levels. GLP-1 secretion is often impaired in people with Type 2 Diabetes. NN9924 is formulated using Emisphere’s Eligen Technology to facilitate absorption from the gut in order to obtain adequate bioavailability. The t...